# Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Source: https://onco.cc/trials/nct03926624/  
OnCo record `nct03926624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of DFP-10917 run by Delta-Fly Pharma, Inc., terminated.

## Summary

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage is a phase 3 interventional study registered as NCT03926624 by Delta-Fly Pharma, Inc., with 167 participants enrolled, started 2019-11-22. Conditions recorded: Leukemia, Myeloid, Acute. Interventions recorded: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax and Cladribine.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03926624
- Phase: 3
- Setting: Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
- Sponsor: Delta-Fly Pharma, Inc.
- Enrolled: 167

## Sources

- ClinicalTrials.gov NCT03926624: https://clinicaltrials.gov/study/NCT03926624

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [DFP-10917](https://onco.cc/drugs/dfp-10917/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct03926624.json